Glenmark Pharmaceuticals Limited has launched a fixed-dose combination (FDC) of its novel, patent protected and globally researched Sodium-Glucose Co-Transporter Inhibitor (SGLT2i) – Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) – Vildagliptin, in India. The fixed drug combination is indicated for the management of Type 2 diabetes. The combination will contain Remogliflozin (100 mg) + Vildagliptin (50 mg) in a fixed-dose and must be taken twice daily. Glenmark has launched the same under two brand names Remo V and Remozen V.
Glenmark is the first company in the world to launch Remogliflozin + Vildagliptin fixed dose combination and India is the first country to get access to this FDC drug. Glenmark received approval from the DCGI for manufacturing and marketing Remogliflozin + Vildagliptin combination. While the average daily cost of therapy of existing brands in the same drug category is Rs. 78, Glenmark’s Remogliflozin-Vildagiptin combination has been launched at Rs. 14 per tablet, to be taken twice daily, which amounts to Rs. 28 as the per day cost of therapy. This cost is 65% lower than other available combination drugs in the market.
